Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: Defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia
Open accessThe DOI matches its Crossref record.
Abstract
Complete bioavailability of i.v. busulfan (Bu) provides dose assurance by reducing the interdose and interpatient variability in Bu systemic exposure (Bu-SE) associated with the oral formulation. We hypothesized that Bu-SE, represented by the area under the plasma concentration versus time curve (AUC), would correlate with treatment outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myelogenous leukemia (CML). Therefore, we analyzed the risk of death, incidence of regimen-related toxicity, and incidence of acute GVHD (aGVHD) as functions of the per dose i.v. Bu AUC in 36 CML patients who received a HSCT from an HLA-matched family donor after the i.v. BuCy2 regimen. Per-dose Bu AUCs were calculated for each subject using data obtained for doses 1, 5, 9, and 13. Toxicity was evaluated using the modified National Cancer Institute criteria. Because no patient developed veno-occlusive disease, increased serum bilirubin was used to characterize hepatotoxicity. We found that the probabilities of developing gastrointestinal toxicity (P = .01), hepatotoxicity (P < .01), mucositis (P = .09), and aGVHD (P < .01) all increased with increasing AUC. Further, the risk of death was significantly lower for patients having a per-dose AUC between approximately 950 and 1520 microMol-min, whereas the risk increased sharply with either lower or higher AUC values. These data suggest that an optimal Bu therapeutic window, based on per-dose AUC, exists. Given the ability of i.v. Bu to provide a more consistent per-dose AUC, these results should be useful in designing future i.v.V Bu-based treatment protocols for stem cell transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
de Lima, M., Couriel, D., Thall, P. F., Wang, X., Madden, T., Jones, R., Shpall, E. J., Shahjahan, M., Pierre, B., Giralt, S., et al. (2004) · Blood · doi:10.1182/blood-2004-02-0414 · Cited by 415
Self-citationBartelink, I. H., Lalmohamed, A., van Reij, E. M. L., Dvorak, C. C., Savic, R. M., Zwaveling, J., Bredius, R. G. M., Egberts, A. C. G., Bierings, M., Kletzel, M., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30114-4 · Cited by 294
Kanter, J., Thompson, A. A., Pierciey, F. J., Hsieh, M., Uchida, N., Leboulch, P., Schmidt, M., Bonner, M., Guo, R., Miller, A., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.26741 · Cited by 134
Harris, A. C., Boelens, J. J., Ahn, K. W., Fei, M., Abraham, A., Artz, A., Dvorak, C., Frangoul, H., Freytes, C., Gale, R. P., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016956 · Cited by 33
Bourget, P., Falaschi, L., Suarez, F., Galland, V., Blot, D., Trompette, C., Sibon, D., Fontbrune, F. S. D., Merlette, C., Vidal, F., et al. (2012) · Bulletin du Cancer · doi:10.1684/bdc.2012.1589 · Cited by 3
Metadata
- Authors
- Andersson, B. S., Thall, P. F., Madden, T., Couriel, D., Wang, X., Tran, H. T., Anderlini, P., de Lima, M., Gajewski, J., & Champlin, R. E.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2002-09
- Volume
- 8
- Issue
- 9
- Pages
- 477-485
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W1992011065
- Cited by
- 227
- References
- 0
- FWCI
- 4.05
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.